Can Thought Field Therapy (TFT) Be Helpful for Patients With an Anxiety Disorder? - Full Text View

Sponsored by:	Sorlandet Hospital HF
Information provided by:	Sorlandet Hospital HF
ClinicalTrials.gov Identifier:	NCT00202709

Purpose

The purpose of this study is to find out if Thought Field Therapy has effect on certain anxiety disorders; agoraphobia, social phobia, and post traumatic stress disorder (PTSD).

Condition	Intervention
Agoraphobia Social Phobia	Behavioral: Thought Field Therapy (TFT)

Study Type:	Interventional
Study Design:	Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Efficacy Study
Official Title:	Can Thought Field Therapy (TFT) Be Helpful for Patients With an Anxiety Disorder, a Prospective, Randomized Pilot Study With Wait List as Control Group.

Resource links provided by NLM:

MedlinePlus related topics: Anxiety Phobias

U.S. FDA Resources

Further study details as provided by Sorlandet Hospital HF:

Primary Outcome Measures:

Global symptom index (gsi) on the Symptom checklist 90 revised (SCL-90-R)

Secondary Outcome Measures:

Davidson Trauma Scale
Liebowitz Social Anxiety Scale
Hospital Anxiety and Depression Scale (HADS)
Fear Questionnaire (FQ)
Sheehan Disability Scale

Estimated Enrollment:	52
Study Start Date:	May 2002
Estimated Study Completion Date:	August 2003

Detailed Description:

Thought Field Therapy is an alternative treatment method that has been shown, by casuistic reports, to give good results when applied for anxiety disorders. In this study 52 patients, with one or more of the diagnoses agoraphobia, social phobia and/or PTSD, where randomized to either treatment with TFT or a wait list. The treatment group all got treatment in one week. 2 1/2 months later both the treatment group and the control group were tested on the same items as before the treatment started. After this evaluation phase the control group got the same treatment as the treatment or study group. Both groups were evaluated 3 and 12 months after treatment, the study group also 6 months after treatment. 4 patients were omitted because they changed groups. The study were performed from May 2002 until June 2003.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

One or more of the study diagnoses agoraphobia, social phobia and/or PTSD

Exclusion Criteria:

Ongoing psychosis
Ongoing serious drug problems

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00202709

Locations

Norway
Sorlandet Hospital
Arendal, Norway, 4809

Sponsors and Collaborators

Sorlandet Hospital HF

Investigators

Principal Investigator:

Audun C Irgens, MD

Sorlandet Hospital HF

More Information

No publications provided

Study ID Numbers:	SSHF-AUIR-1
Study First Received:	September 12, 2005
Last Updated:	September 12, 2005
ClinicalTrials.gov Identifier:	NCT00202709 History of Changes
Health Authority:	Norway: The National Committees for Research Ethics in Norway

Keywords provided by Sorlandet Hospital HF:

Anxiety disorder
Thought Field Therapy
Psychotherapy

Agoraphobia
Social Phobia
Posr Traumatic Stress Disorder

Study placed in the following topic categories:

Anxiety Disorders
Mental Disorders
Agoraphobia

Stress
Phobic Disorders
Stress Disorders, Traumatic

Additional relevant MeSH terms:

Anxiety Disorders
Mental Disorders
Agoraphobia
Phobic Disorders

ClinicalTrials.gov processed this record on September 11, 2009